Board approved audited standalone and consolidated FY26 results, with auditors issuing a modified opinion due to an unresolved insurance claim of ₹98.19 million from a subsidiary's fire incident.
Appointed M/s Pipalia Singhal & Associates as internal auditors for FY27 and reconstituted Senior Managerial Personnel, including new COO and Business Director.
Approved fresh equity issuance in subsidiary Rivadu Lifesciences, conditional on maintaining at least 51% ownership, with details to be disclosed post-allotment.
Consolidated revenue grew to ₹4,504.41 million in FY26 from ₹3,922.61 million in FY25, with net profit at ₹512.30 million.